Humacyte (HUMA) Share-based Compensation (2020 - 2026)

Humacyte (HUMA) has 7 years of Share-based Compensation data on file, last reported at $3.2 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.2 million, up 27.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (up 56.79% YoY), and the FY2025 annual result was $10.4 million, up 69.64% from the prior year.
• Share-based Compensation climbed to $3.2 million in Q1 2026 per HUMA's latest filing, from $3.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $3.2 million in Q1 2026 and troughed at $1.4 million in Q4 2023.
• A 5-year average of $1.9 million and a median of $1.7 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation slumped 49.11% in 2022, then jumped 84.65% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $1.7 million in 2022, then dropped by 15.81% to $1.4 million in 2023, then climbed by 20.48% to $1.7 million in 2024, then jumped by 84.65% to $3.1 million in 2025, then rose by 1.34% to $3.2 million in 2026.
• Business Quant data shows HUMA's Share-based Compensation at $3.2 million in Q1 2026, $3.1 million in Q4 2025, and $2.5 million in Q3 2025.